News

After the transaction, Global Pharm obtained the new business license for Bozhou Xinghe, with registered capital of $3.1m. Under the terms of this acquisition, Global Pharm will pay

The products are based on the hormones ethinylestradiol (estrogen) and drospirenone. The EPO’s decision was backed by an appeal from Hexal (Sandoz) which was filed in 2006 against

The double-blind, randomized and placebo-controlled trial will recruit around 48 healthy subjects and 20 HCV genotype 1 treatment naive patients in the US. Achillion president and CEO Michael

China-based Chongqing Lummy is engaged in research, development, manufacture and sale of anti-infective, oncology and nutritional parenteral products. With this agreement, Sagent intends to strengthen its presence in

The expansion helps CIS display platform for the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment. The development further brings additional

The results of the trial suggested that Adva-27 is 16-times more effective at killing Multidrug Resistant Breast Cancer cells in comparison to Etoposide. Additionally, the data from the

Caduet Combination Tablets are oral combination drug of Norbasc Tablets and Lipitor Tablets. Under the agreement, Pfizer is responsible to seek marketing approval for the product in Japan,

The company said the decision is still subject to the approval of board members. Most recently, Kress worked as the vice president and general manager for Gilead France

AMT has developed Glybera for the treatment of patients who are suffering from genetic disorder lipoprotein lipase deficiency (LPLD). The re-examination of the dossier is expected to be